Biotech News

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal (MDGL)MadrigalEarnings

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.

Related news

Madrigal

MASH-Focused Biopharmaceutical Company Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation. The company is building a specialized commercial and clinical-development organization around therapies that...

Recent company news

Stock data

Close
396.74 USD
Market cap
10.44B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States